Page 3 of 3: studies 41 to 56 of 56, newest first. Back to the ketamine overview
The Brown University Psychopharmacology Update March 1, 2015
A new randomized, double‐blind crossover study has found that a single 50‐mg dose of intranasal ketamine was associated with rapid antidepressant response in patients with treatment‐resistant depression, with a significant effect seen 40 minutes after administration.
Annals of the New York Academy of Sciences February 27, 2015 Chadi G. Abdallah, Lynnette A. Averill, John H. Krystal 117 citations
The discovery of ketamine's rapid and robust antidepressant effects opened a window into a new generation of antidepressants. Multiple controlled trials and open-label studies have demonstrated these effects across a variety of patient populations known to often achieve little to no response from traditional antidepressants. Ketamine has been generally well tolerated across patient groups, with...
Translational Psychiatry February 17, 2015 James W. Murrough, Katherine A. Collins, Jessica Fields et al. 111 citations
The glutamate N-methyl-D-aspartate receptor antagonist ketamine has demonstrated antidepressant effects in individuals with treatment-resistant major depressive disorder (TRD) within 24 h of a single dose. The current study utilized functional magnetic resonance imaging (fMRI) and two separate emotion perception tasks to examine the neural effects of ketamine in patients with TRD. One task used...
Journal of Psychopharmacology February 17, 2015 Níall Lally, Allison C. Nugent, David A. Luckenbaugh et al. 224 citations
Anhedonia is a cardinal symptom of major depression and is often refractory to standard treatment, yet no approved medication for this specific symptom exists. In this exploratory re-analysis, we assessed whether administration of rapid-acting antidepressant ketamine was associated specifically with reduced anhedonia in medication-free treatment-refractory patients with major depressive...
Annals of the New York Academy of Sciences February 3, 2015 Kaitlin E. DeWilde, Cara F. Levitch, James W. Murrough et al.
Major depressive disorder (MDD) is one of the most disabling diseases worldwide and is becoming a significant public health threat. Current treatments for MDD primarily consist of monoamine‐targeting agents and have limited efficacy. However, the glutamate neurotransmitter system has recently come into focus as a promising alternative for novel antidepressant treatments. We review the current...
Experimental Biology and Medicine February 1, 2015 Ke Xu, Robert H Lipsky
For more than 40 years following its approval by the Food and Drug Administration (FDA) as an anesthetic, ketamine, a non-competitive N-methyl-d-aspartic acid (NMDA) receptor antagonist, has been used as a tool of psychiatric research. As a psychedelic drug, ketamine induces psychotic symptoms, cognitive impairment, and mood elevation, which resemble some symptoms of schizophrenia. Recreational...
Therapeutic Advances in Psychopharmacology February 1, 2015 Hannah Steeds, Robin Carhart-Harris, James Stone 132 citations
Schizophrenia is a complex mental health disorder with positive, negative and cognitive symptom domains. Approximately one third of patients are resistant to currently available medication. New therapeutic targets and a better understanding of the basic biological processes that drive pathogenesis are needed in order to develop therapies that will improve quality of life for these patients....
Psychiatry Research January 30, 2015 C. Kellner, S. Lisanby, Richard D. Weiner et al.
Electroconvulsive therapy (ECT) has long been regarded as the standard for quick antidepressant response. Recently, ketamine has been touted as an even faster antidepressant, notably in the report by Ghasemi et al. (2014) in which 18 patients (nine in each group) were given three intravenous ketamine infusions or three ECT treatments and followed for 1 week (Ghasemi et al., 2014). While the...
The International Journal of Neuropsychopharmacology January 29, 2015 Chi‐Tso Chiu, Lisa Scheuing, Guangping Liu et al.
Background: Evidence suggests that mammalian target of rapamycin activation mediates ketamine’s rapid but transient antidepressant effects and that glycogen synthase kinase-3β inhibits this pathway. However, ketamine has associated psychotomimetic effects and a high risk of abuse. The mood stabilizer lithium is a glycogen synthase kinase-3 inhibitor with strong antisuicidal properties. Here, we...
2015 S. Verma
Background and Objective: The objective was to evaluate clinical trial data on the use of ketamine in treating treatment-resistant depression (TRD). Materials and Methods: PubMed search (November 2012) was initiated using the keywords: Ketamine, resistant depression. Inclusion criterion included: English language publications describing clinical trial reports on humans with TRD. Results: A...
Psychiatria Polska 2015 K. Kucia, W. Merk
In recent years, data on the possibility of rapid clinical improvement after administration of ketamine in patients diagnosed with depression have been published more frequently. Ketamine, used as an anaesthetic during ECT procedures, despite earlier concerns, has both: a good safety profile and minimal effect on seizure threshold, which is used in cases of non-response to ECT. Postulated...
Neural Plasticity 2015 Annie J. Xu, Mark J. Niciu, Nancy B. Lundin et al. 27 citations
Ketamine and lithium both inhibit glycogen synthase kinase 3. In addition, lithium and ketamine have synergistic antidepressant-like effects at individually subeffective doses in rodents. We hypothesized that ketamine's antidepressant effects would be improved by therapeutic doses of lithium versus valproate and that serum lithium levels would positively correlate with ketamine's antidepressant...
Frontiers in Psychiatry 2015 Charles F Zorumski, Peter Nagele, Steven Mennerick et al.
Major depressive disorder (MDD) remains a huge personal and societal encumbrance. Particularly burdensome is a virulent subtype of MDD, treatment resistant major depression (TMRD), which afflicts 15-30% of MDD patients. There has been recent interest in N-methyl-d-aspartate receptors (NMDARs) as targets for treatment of MDD and perhaps TMRD. To date, most pre-clinical and clinical studies have...
Depression Research and Treatment 2015 Basant Pradhan, Tapan Parikh, Ramkrishna Makani et al. 24 citations
Depression affects about 121 million people worldwide and prevalence of major depressive disorder (MDD) in US adults is 6.4%. Treatment resistant depression (TRD) accounts for approximately 12–20% of all depression patients and costs $29–$48 billion annually. Ketamine and repetitive transcranial magnetic stimulation (rTMS) have useful roles in TRD, but their utility in long term is unknown. As...
American Journal on Addictions 2015 James X. Liu, Erin Zerbo, Stephen Ross 17 citations
Ketamine is known within the medical field for its anesthetic properties, yet its unique psychedelic and antidepressant properties are being increasingly recognized. We document the case of a patient with bipolar I disorder and an extensive history of substance dependence who used large doses of ketamine (1-3 g) on a daily basis over a period of 5 years, and described acute antidepressant...
The British Journal of Psychiatry 2015 Ben Sessa, Matthew W. Johnson 58 citations
Summary After a 40-year hiatus there is now a revisiting of psychedelic drug therapy throughout psychiatry, with studies examining the drugs psilocybin, ketamine, ibogaine and ayahuasca in the treatment of drug dependence. Limitations to these therapies are both clinical and legal, but the possibility of improving outcomes for patients with substance dependency imposes an obligation to research...